Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9664891 | 0.77 | ALDH1A1 (0.62) | TRPA1ALDH1A1TSHRHIF1ALMNA | |
| SCHEMBL30029908 | 0.77 | ALDH1A1 (0.49) | TRPA1ALDH1A1TSHRHIF1ALMNA | |
| SCHEMBL8660409 | 0.77 | ALDH1A1 (0.49) | TRPA1ALDH1A1TSHRHIF1ALMNA | |
| SCHEMBL1629226 | 0.76 | ALDH1A1 (0.47) | TRPA1ALDH1A1TSHRHIF1ALMNA | |
| SCHEMBL27782003 | 0.74 | TRPA1 (0.50) | TRPA1ALDH1A1TSHRCYP2C19MAPT | |
| SCHEMBL28256581 | 0.74 | TRPA1 (0.50) | TRPA1ALDH1A1TSHRHIF1ALMNA | |
| SCHEMBL1125095 | 0.74 | TRPA1 (0.50) | TRPA1ALDH1A1TSHRLMNACYP2C19 | |
| SCHEMBL9501889 | 0.74 | TRPA1 (0.50) | TRPA1ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL2163244 | 0.74 | ALDH1A1 (0.46) | ALDH1A1TSHRHIF1ALMNACYP2C19 | |
| SCHEMBL2245671 | 0.74 | ALDH1A1 (0.46) | TRPA1ALDH1A1TSHRHIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130227-A1 | PRODRUGS OF ANTI-PLATELET AGENTS | CELLIX BIO PRIVATE LTD (IN) | 2016-05-12 | — | — | US | disclosed |
| US-20160130227-A1 | PRODRUGS OF ANTI-PLATELET AGENTS | CELLIX BIO PRIVATE LTD (IN) | 2016-05-12 | — | — | US | disclosed |
| US-9175008-B1 | Prodrugs of anti-platelet agents | CELLIX BIO PRIVATE LIMITED (IN) | 2015-11-03 | — | — | US | disclosed |
| US-7932391-B2 | Using halogen phenyl acetonitrile as starting material; tetrahydrothienopyridine (acetate or acetonitrile) as chemical intermediates; kinetic resolution; anticoagulant | Zhejiang Hauhai Pharmaceutical Co., Ltd. (CN) | 2011-04-26 | — | — | US | disclosed |
| US-20080249311-A1 | Using halogen phenyl acetonitrile as starting material; tetrahydrothienopyridine (acetate or acetonitrile) as chemical intermediates; kinetic resolution; anticoagulant | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2008-10-09 | — | — | US | disclosed |
| EP-1942110-A1 | PREPARATION OF CLOPIDOGREL AND ITS ANALOGUES METHYL TETRAHYDROTHIENOPYRIDINE ACETATE COMPOUNDS | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2008-07-09 | — | — | EP | disclosed |
| US-7169777-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169777-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| EP-0823908-B1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20040116699-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-06-17 | — | — | US | disclosed |
| US-5733914-A | Pyrido 2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation | WARNER-LAMBERT COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| US-5733913-A | TREATING ATHEROSCLEROSIS, POSTSURGICAL RESTENOSIS | WARNER-LAMBERT COMPANY | 1998-03-31 | — | — | US | disclosed |
| EP-0823908-A1 | PYRIDO 2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1998-02-18 | — | — | EP | disclosed |
| CN-1169726-A | 6-aryl pyrido (2,3-d) pyrimidines and naphthyridines for inhibiting protein tyrosine kinase medicated cellular proliferation | WARNER LAMBERT CO (US) | 1998-01-07 | — | — | CN | disclosed |
| EP-0790997-A2 | 6-ARYL PYRIDO( 2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996034867-A1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-11-07 | — | — | WO | disclosed |
| WO-1996015128-A2 | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-05-23 | — | — | WO | disclosed |
| EP-0018151-B1 | 6-SUBSTITUTED-ARYLPYRIDO(2,3-D)PYRIMIDIN-7-AMINES, DERIVATIVES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING ANY OF THE FOREGOING, AND PROCESSES FOR PRODUCING ANY OF THE FOREGOING | WARNER-LAMBERT COMPANY (US) | 1984-01-25 | — | — | EP | disclosed |
| US-4271164-A | HYPOTENSIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1981-06-02 | — | — | US | disclosed |
| EP-0018151-A1 | 6-Substituted-arylpyrido(2,3-d)pyrimidin-7-amines, derivatives and salts thereof, pharmaceutical compositions containing any of the foregoing, and processes for producing any of the foregoing | WARNER-LAMBERT COMPANY (US) | 1980-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249311-A1 | Using halogen phenyl acetonitrile as starting material; tetrahydrothienopyridine (acetate or acetonitrile) as chemical intermediates; kinetic resolution; anticoagulant | TFPI, F2, CYP2C19 | TRPA1 124/4885ALDH1A1 579/4885TSHR 259/4885 |
| US-20160130227-A1 | PRODRUGS OF ANTI-PLATELET AGENTS | F12, F2, PLAT | TRPA1 1417/4885ALDH1A1 811/4885TSHR 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.